Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $212K | $127K | $11.4M | $13.4M | $10.9M | $9.77M | $9.51M | $7.42M |
| Revenue growth | — | -40.2% | 8872.0% | 17.3% | -18.2% | -10.6% | -2.7% | -21.9% |
| Gross profit | $28.8K | $55.9K | $1.72M | $2.27M | $1.26M | $1.33M | $1.29M | $1.09M |
| Gross margin | 13.5% | 44.0% | 15.1% | 17.0% | 11.5% | 13.6% | 13.6% | 14.6% |
| Operating income | $59.9K | -$276K | $1.27M | $1.06M | -$291K | -$2.59M | -$1.57M | -$2.97M |
| Operating margin | 28.2% | -217.2% | 11.2% | 7.9% | -2.7% | -26.5% | -16.5% | -39.9% |
| Net income | $26.5K | -$246K | $1.09M | $752K | -$356K | -$2.63M | -$1.60M | -$2.98M |
| Net margin | 12.5% | -194.1% | 9.6% | 5.6% | -3.3% | -26.9% | -16.8% | -40.2% |
| EPS (diluted) | $0.00 | $0.00 | $0.01 | — | — | -$0.17 | -$0.09 | — |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$274K | -$217K | $553K | $9.16K | $552K | -$1.82M | -$2.09M | -$1.84M |
| Capital expenditures | -$39.6K | $12.8K | $422K | $3.16K | $0.00 | $149K | $227K | $37.0K |
| Free cash flow | -$234K | -$230K | $131K | $6.00K | $552K | -$1.97M | -$2.32M | -$1.88M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.26M | $859K | $2.79M | $2.12M | $2.12M | $4.52M | $2.89M | $2.49M |
| Total assets | $1.65M | $1.23M | $10.1M | $9.57M | $8.74M | $11.4M | $10.4M | $9.25M |
| Total liabilities | $130K | $109K | $3.45M | $2.39M | $2.08M | $1.74M | $2.11M | $638K |
| Shareholders' equity | $1.52M | $1.12M | $6.66M | $7.18M | $6.67M | $9.66M | $8.32M | $8.61M |
| Retained earnings | -$86.8K | -$333K | $761K | $1.51M | $1.16M | -$1.84M | -$3.44M | -$6.43M |
| Shares (wtd avg diluted) | 74.6M | 103M | 171M | 171M | 14.5M | 17.7M | 1.80M | 2.42M |
Every figure is extracted from BioNexus Gene Lab Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.